biotechnology - GigaVitamin

A promising sickle cell pill and a new way to treat myelofibrosis

CNRI/SCIENCE PHOTO LIBRARY Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. ...

BridgeBio’s great week, Moderna’s fall

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is ...

Novartis to acquire RNA-focused Avidity Biosciences for B

Novartis to acquire RNA-focused Avidity Biosciences for $12B

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45.LONDON — Novartis said Sunday ...

Moderna’s key study of CMV vaccine, expected to be next big win, failed

Moderna said Wednesday afternoon that its experimental vaccine for cytomegalovirus, a cause of disability in newborns, failed in a Phase 3 trial, a ...

Enhertu shows promise as treatment for early breast cancer at ESMO 2025

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45.BERLIN — Enhertu has become ...

Drew Weissman refutes RFK Jr. adviser’s claims about Covid shots

On Thursday and Friday, the Centers for Disease Control and Prevention held a meeting of its Advisory Committee on Immunization Practices, a key ...

Who is involuntary commitment for?

First Opinion is STAT’s platform for interesting, illuminating, and provocative articles about the life sciences writ large, written by biotech insiders, health care ...

Sarepta Therapeutics’ Duchenne therapy crisis has a clear lesson

In a matter of a few days last week, Sarepta Therapeutics announced major layoffs, acknowledged the death of another patient receiving one of ...

Tag: biotechnology